Potomac Pharma, Inc.
http://www.potomacpharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Potomac Pharma, Inc.
Business & Technology Briefs (08/2007)
Brief summaries of recent product and company developments in the device industry, including the demise of GE's proposed $8 billion acquisition of Abbott Diagnosticss, the Cytyc/Hologic merger, and Alsius' SPAC merger.
Start-Up Previews (4/05)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Building a Better Drug for Schizophrenia, features profiles of Galenea Corp., Potomac Pharma Inc., Vanda Pharmaceuticals Inc. and Xytis Pharmaceuticals Ltd. Plus these Start-Ups Across Health Care: Aqueduct Medical Inc., CryoFluor Therapeutics LLC, 3DM Inc. and Xigen SA.
Potomac Pharmaceuticals Inc.
Off-label use of multiple drugs has become a widespread clinical practice in treating schizophrenia. Potomac Pharma Inc. aims to improve outcomes by developing a highly selective alpha-2 antagonists for adjunctive use in treating neurological and psychiatric disorders.
Building a Better Drug for Schizophrenia
Start-ups in pursuit of novel targets are capturing the attention of venture capitalists.
Company Information
- Industry
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice